文献速递临床试验与 GCP

氨甲环酸治疗急性消化道出血(HALT-IT 试验):一项国际、随机、双盲、安慰剂对照试验的统计分析计划

Tranexamic acid for acute gastrointestinal bleeding (the HALT-IT trial): statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Trials · 2019-07-30

HALT-IT 试验为国际随机双盲安慰剂对照试验,纳入 12,000 例急性上或下消化道出血成人,随机接受氨甲环酸(1 g 负荷剂量后 24 小时内 3 g 维持剂量)或匹配安慰剂。主要分析按意向性治疗比较两组,主要结局为随机化后 5 天内出血死亡,结果以相对危险度和置信区间呈现。本统计分析计划在治疗分配揭盲前发布。

要点

  • HALT-IT 试验计划纳入 12,000 例急性上或下消化道出血成人,随机接受氨甲环酸或安慰剂。
  • 氨甲环酸给药方案为 1 g 负荷剂量后 24 小时内 3 g 维持剂量。
  • 主要结局为随机化后 5 天内出血死亡,按意向性治疗分析并以相对危险度呈现。

核心结论

  • HALT-IT 试验旨在提供氨甲环酸治疗急性上消化道和下消化道出血效果与安全性的可靠证据。

研究设计与样本

  • HALT-IT 为国际、随机、双盲、安慰剂对照试验,纳入 12,000 例急性上消化道或下消化道出血成人(由 8000 例增加至 12,000 例)。
  • 合格患者随机分配接受氨甲环酸(1 g 负荷剂量后 24 小时内 3 g 维持剂量)或匹配安慰剂。
  • 主要分析按意向性治疗比较氨甲环酸组与安慰剂组,结果以效应估计值(相对危险度)和置信区间呈现。

主要发现

  • 主要结局为随机化后 5 天内出血死亡。
  • 次要结局包括再出血、全因死亡和特异原因死亡、血栓栓塞事件、并发症、内镜/放射学和外科干预、输血需求、残疾(以患者自我照护能力衡量)以及重症监护或高依赖病房住院天数。
  • 主要结局的亚组分析将考虑治疗时间、出血部位、出血原因和临床 Rockall 评分。

局限性

  • 由于现有试验存在方法学弱点且规模较小,氨甲环酸在消化道出血中的有效性和安全性尚不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute gastrointestinal (GI) bleeding is an important cause of mortality worldwide. Bleeding can occur from the upper or lower GI tract, with upper GI bleeding accounting for most cases. The main causes include peptic ulcer/erosive mucosal disease, oesophageal varices and malignancy. The case fatality rate is around 10% for upper GI bleeding and 3% for lower GI bleeding. Rebleeding affects 5-40% of patients and is associated with a four-fold increased risk of death. Tranexamic acid (TXA) decreases bleeding and the need for blood transfusion in surgery and reduces death due to bleeding in patients with trauma and postpartum haemorrhage. It reduces bleeding by inhibiting the breakdown of fibrin clots by plasmin. Due to the methodological weaknesses and small size of the existing trials, the effectiveness and safety of TXA in GI bleeding is uncertain. The Haemorrhage ALleviation with Tranexamic acid - Intestinal system (HALT-IT) trial aims to provide reliable evidence about the effects of TXA in acute upper and lower GI bleeding. METHODS: The HALT-IT trial is an international, randomised, double-blind, placebo-controlled trial of tranexamic acid in 12,000 adults (increased from 8000) with acute upper or lower GI bleeding. Eligible patients are randomly allocated to receive TXA (1-g loading dose followed by 3-g maintenance dose over 24 h) or matching placebo. The main analysis will compare those randomised to TXA with those randomised to placebo on an intention-to-treat basis, presenting the results as effect estimates (relative risks) and confidence intervals. The primary outcome is death due to bleeding within 5 days of randomisation and secondary outcomes are: rebleeding; all-cause and cause-specific mortality; thromboembolic events; complications; endoscopic, radiological and surgical interventions; blood transfusion requirements; disability (defined by a measure of patient's self-care capacity); and number of days spent in intensive care or high-dependency units. Subgroup analyses for the primary outcome will consider time to treatment, location of bleeding, cause of bleed and clinical Rockall score. DISCUSSION: We present the statistical analysis of the HALT-IT trial. This plan was published before the treatment allocation was unblinded. TRIAL REGISTRATION: Current Controlled Trials, ID: ISRCTN11225767. Registered on 3 July 2012; Clinicaltrials.gov, ID: NCT01658124. Registered on 26 July 2012.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Brenner A, Afolabi A, Ahmad SM, et al. Tranexamic acid for acute gastrointestinal bleeding (the HALT-IT trial): statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial. Trials. 2019. PMID: 31362765. doi:10.1186/s13063-019-3561-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。